每经AI快讯，9月9日，舒泰神（300204）(300204.SZ)公告称，拟定增募资不超过12.53亿元，用于创新 药物研发项目、补充流动资金。 ...

2025年9月8日，舒泰神（北京）生物制药股份有限公司发布公告，鉴于拟向特定对象发行股票，公司对 近五年是否被证券监管部门和交易所采取监管措施或处罚进行自查。结果显示，公司近五年不存在被处 罚情况。监管措施方面，2020年因特定关联交易违反首发承诺，深交所下发问询函，中国证监会北京监 管局对公司及董事长采取监管谈话措施。公司高度重视并整改，与关联方协商收益返还等事宜，相关人 员接受监管谈话，还组织学习证券法规，加强关联交易管理。除上述情形，无其他监管措施情况。 ...

（编辑 楚丽君） 证券日报网讯 9月5日晚间，舒泰神发布公告称，持股5%以上股东香塘集团有限公司将其所持有的部分 股份解除质押，本次解除质押股数为250万股，占其所持股份比例6.81%，占公司总股本比例0.52%，质 权人为中国农业银行股份有限公司太仓分行。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-052 | 苏州香塘同 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 轩科技有限 | | 4.5067 | 0.01% | 0 | 0% | 0% | 0 | 0% | 0 | 0% | | 公司 | | | | | | | | | | | | 合 | 计 | 3,674.0075 | 7.69% | 3,005.0000 | 81.89% | 6.29% | - | - | - | - | 三、备查文件 舒泰神（北京）生物制药股份有限公司 关于股东部分股份解除质押的公告 持股 5%以上股东香塘集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏 舒泰神（北京）生物制药股份有限公司（以下简称"本公司"或"舒泰神"） 近日接到持股 5%以上股东香塘集团有限公司（以下简称"香塘集团 ...

创新药概念股盘中走低，舒泰神、前沿生物跌超10%，福元医药跌停，百花医药、亚太药业、万邦德、 百利天恒、睿智医药等多股跌超5%。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.89% on September 2, with Shuyatian leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Ziji Shenzhou (688235) with a closing price of 324.85, up 8.28% [1] - Mengke Pharmaceutical (688373) at 8.26, up 8.12% [1] - Haichen Pharmaceutical (300584) at 68.49, up 7.22% [1] - Other significant performers included: - Beilu Pharmaceutical (300016) at 10.78, up 6.94% [1] - Warner Pharmaceutical (688799) at 56.73, up 5.56% [1] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.388 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.034 billion yuan [4] - Key stocks with notable capital flows included: - Baijishenzhou (688235) with a net inflow of 1.56 billion yuan from institutional investors [4] - Beilu Pharmaceutical (300016) with a net outflow of 41.53 million yuan from retail investors [4] ETF Information - The Huaxia Sci-Tech 100 ETF (product code: 588800) tracks the Shanghai Stock Exchange Sci-Tech 100 Index and has seen a 4.38% change over the last five days [6] - The current PE ratio stands at 231.01, with a recent reduction in shares by 65 million, indicating a net outflow of 782,000 yuan from institutional investors [6]

近日，公募基金2025年中报披露结束。从行业配置来看，今年上半年，医药生物、银行、电子等板块的 基金持股市值显著增长，而电力设备、食品饮料、煤炭等板块则出现较大下降。截至报告期末，电子、 医药生物、电力设备仍为基金持仓规模最大的三大行业。个股方面（仅统计A股），舒泰神、昂利康、 潍柴重机在基金持股占流通市值比例增长方面包揽前三席，而从基金持股市值增长情况来看，国泰海 通、胜宏科技、紫金矿业排名领先。在基金持股集中度方面，诺诚健华、茂莱光学、德科立位列基金持 股占流通股比例前三名，宁德时代、贵州茅台、招商银行则位居基金持股市值排行榜前三。 ...

Core Viewpoint - The stock of Shuyou Shen has experienced significant fluctuations, with a year-to-date increase of 587.45%, but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of August 29, Shuyou Shen's stock price was 50.94 CNY per share, with a market capitalization of 24.338 billion CNY [1]. - The stock has seen a trading volume of 3.21 billion CNY, with a turnover rate of 1.36% [1]. - Year-to-date, the stock has risen by 587.45%, but has decreased by 2.99% in the last five trading days and 2.17% in the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14% [2]. - The net profit attributable to shareholders was -24.636 million CNY, representing a year-on-year decrease of 619.70% [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700 [2]. - The average number of circulating shares per shareholder decreased by 22.60% to 14,327 shares [2]. - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, several new institutional shareholders have emerged among the top ten circulating shareholders, including: - Xingquan Helun Mixed A (163406) as the third-largest shareholder with 15.721 million shares [3]. - Xingquan Commercial Model Mixed (LOF) A (163415) as the fifth-largest shareholder with 8.805 million shares [3]. - Other new shareholders include Xingquan New Vision and Yongying Medical Innovation [3].

Group 1 - The A-share market's innovative drug concept stocks have experienced a collective decline for the third consecutive day, with notable drops including Nanjing New Pharmaceutical falling over 11% and Yuandong Bio down over 9% [2] - Other companies such as Borui Pharmaceutical, Zhaoyan New Drug, and Kangyuan Pharmaceutical also saw declines exceeding 6%, while Shutaishen, Hite Bio, Shouyao Holdings, and Wanbangde dropped over 5% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [3]

Core Viewpoint - The innovative pharmaceutical company Shutaishen has seen its stock price increase by over 600% this year despite facing significant financial losses and declining sales of its main products [1][10]. Financial Performance - In the first half of 2025, Shutaishen reported revenue of 126 million CNY, a year-on-year decrease of 31.14% [4]. - The company recorded a net loss attributable to shareholders of 24.64 million CNY, a substantial decline of 619.70% compared to the previous year [4]. - Cumulative losses since 2020 have exceeded 1 billion CNY, with the company experiencing continuous losses for several years [6]. Product Sales - The main products, Sutai Sheng and Shutaqing, have seen disappointing sales in the first half of the year, with Sutai Sheng generating 74.32 million CNY (down 5.71% year-on-year) and Shutaqing generating 41.69 million CNY (down 57.88% year-on-year) [7][8]. - The decline in sales is attributed to external factors and changes in industry policies, particularly affecting Shutaqing due to its exclusion from the latest national procurement list [8]. Research and Development - Shutaishen is focusing on product iteration and accelerating the launch of its research pipeline to address its performance challenges [8]. - The company has launched new products targeting constipation and has advanced its fourth-generation product STSP-0902 into clinical trials [8][10]. - Research and development expenses amounted to 65.05 million CNY, representing 51.79% of total revenue, indicating a significant investment in future product development [10]. Market Position and Stock Performance - The stock price of Shutaishen has surged significantly, influenced by the overall growth in the innovative pharmaceutical sector and positive developments regarding its product STSP-0601 [10]. - The company has received substantial investment from the Jin Yi Yuan Li Fund, which has bolstered its financial position [11]. - Despite the stock price increase, analysts caution about potential market corrections due to the overall weak market performance [10].